Skip to content

A randomized controlled trial of taurine intervention in hyperuricemia with hypercholesterolemia

A randomized controlled trial of taurine intervention in hyperuricemia with hypercholesterolemia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062286
Enrollment
Unknown
Registered
2022-07-31
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia with hypercholesterolemia

Interventions

Experimental group:Taurine, allopurinol
Control group:Placebo, allopurinol

Sponsors

The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for hyperuricemia with TC levels between 5.2 and 7.2 mmol/L; 2. Aged 18-60 years, male; 3. No recent (> 8 weeks) use of drugs that affect blood uric acid metabolism, including benzofuran derivatives (phenylbromarone, phenyliododarone), prosulfa, colchicine, salicylate (aspirin), selective and non-selective non-steroidal anti-inflammatory drugs, thiazines, furosemide diuretics, cyclosporin, pyrazinamide, losartan, etc., and patients who have taken other uric acid lowering measures; Or have stopped the drug for more than 2 weeks; 4. Cooperate with various research inspections and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary hyperuricemia; 2. Gout or clinical manifestations of gout, including acute gouty arthritis, gouty stone and chronic arthritis, severe deformities, incapacitated persons, renal lesions; 3. Complicated with serious diseases of the heart, lung, brain, liver, kidney, hematopoietic system, including hepatitis B or C virus, kidney stones, polycystic kidney disease, hematologic malignancies or other unconfirmed malignant diseases and HIV; 4. Patients with a history of organ transplantation or extracorporeal circulation surgery; 5. Patients who participated in clinical trials of other drugs within 3 months; 6. The mentally ill; 7. Allergic constitution and multiple drug allergy (known allergy to allopurinol).

Design outcomes

Primary

MeasureTime frame
Blood uric acid;Total cholesterol;

Secondary

MeasureTime frame
Blood creatinine;Urinary acid;24-hour uric acid excretion index;Urine creatinine;Triglyceride;Low density lipoprotein-cholesterol;High density lipoprotein-cholesterol;

Countries

China

Contacts

Public ContactFu Bin
doctorfubin@126.com+86 22 60637143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026